1Gorman CA. Radiotheraoy for Graves' ophthaimopathy: resulta at one year[ J] .Thyroid.2002.12(3) :251-256.
2Burch HB, Wartofsky L. Gravest ophthalmopathy: current concepts regarding pathogenesis and management [ J ] , Endocr Rev, 1993,14 (6) : 747-793,.
3Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy[ J]. N Engl J Med, 1993,329(20) : 1468-1475.
4Gerding MN,Terwee CB, Dekker FW, et al. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument [ J ]. Thyroid, 1997,7 (6) : 885-889.
5Geoffrey J, Gladstone MD. Opbthalmologic aspects of thyroid-related orbitopathy[ J]. Endocrinol Metab Clin North Am, 1998,27 ( 1 ) :91-100.
7Mouritis MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach[J] ,Br J Ophthalmol,1989,73(8) :639-644.
8Mouritis IMP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves'ophthalmopathy[J].Clin Endocrinol(Oxf),1997,47(1):9-14.
9Pete P, Crombie AL, Kendall-Taylor P. Natural history of thyroid-associated ophthalmopathy[ J ]. Clin Endocrinol (Oxf), 1995,42( 1 ) : 45-50.
10Bartley GB, Fatourechi V, Kadrmas EF, et al. The treatment of Graves'ophthalmopathy in an incidence cohort [ J ]. Am J Ophthalmol, 1996,121(2) :200-206.
